Description
EMEND (aprepitant) is a medication prescribed to treat chemotherapy-induced nausea and vomiting (CINV). EMEND should only be used under the close supervision of a doctor that treats cancer (oncologist).
EMEND is approved to treat CINV in patients who are being treated with moderate or highly emetogenic chemotherapy. It can also be used to prevent postoperative nausea and vomiting (PONV).
EMEND works by blocking NK1 receptors. NK1 receptors are involved in causing nausea and vomiting, so blocking these receptors helps to prevent this response.
Directions
Take EMEND exactly as prescribed by the oncologist. EMEND capsules should only be used by adults and pediatric patients that are 12 years or older.
The normal dose is 125 mg by mouth one hour before chemotherapy on day 1, and 80 mg by mouth one hour before chemotherapy on days 2 and 3.
EMEND can be taken with or without food.
Swallow EMEND capsules whole without opening or chewing.
Ingredients
The active ingredient in EMEND is aprepitant.
Interactions
EMEND has the potential to cause many different drug-drug interactions. Speak with your oncologist about all medications that you are taking.
- Benzodiazepines
- Carbamazepine
- Clarithromycin
- Dexamethasone
- Diltiazem
- Dolasetron
- Granisetron
- Hormonal contraceptives
- Itraconazole
- Ketoconazole
- Methylprednisolone
- Nefazodone
- Nelfinavir
- Ondansetron
- Phenytoin
- Pimozide
- Rifampin
- Ritonavir
- Troleandomycin
- Warfarin
Cautions
EMEND should not be used as a long-term medication to treat nausea and vomiting.
Side Effects
The list of EMEND side effects includes:
- Abdominal pain
- Asthenia
- Constipation
- Cough
- Decreased appetite
- Decreased white blood cells
- Dehydration
- Diarrhea
- Dizziness
- Dyspepsia
- Fatigue
- Headache
- Hiccups
- Hypotension
- Increased liver enzymes
- Neutropenia
Speak with your oncologist to review the full list of adverse reactions that may apply to your specific situation.
References
- Emend [package insert]. Whitehouse Station, NC: Merck; 2015.
Fact Table |
Formula |
C23H21F7N4O3 |
License |
AU, EU EMA, US FDA |
Bioavailability |
60-65% |
Legal status |
RX Only |
Chemical Name |
Aprepitant |
Elimination half-life |
9-13 hours |
Dosage (Strength) |
80mg (2 tablets), 1x125+2x80mg (3 capsules) |
Pregnancy |
Consult a doctor |
Brands |
Cinvanti, Emend |
Protein binding |
less than 95% |
PubChem CID |
6918365 |
MedlinePlus |
a604003 |
ChEBI |
499361 |
ATC code |
A04AD12 |
DrugBank |
DB00673 |
KEGG |
D02968 |
Routes of administration |
By mouth |
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 10098